Lexaria Bioscience Corp (LEXX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Lexaria Bioscience Corp stock (LEXX) is currently trading at $0.77. Lexaria Bioscience Corp PS ratio (Price-to-Sales) is 34.80. Analyst consensus price target for LEXX is $3.75. WallStSmart rates LEXX as Sell.
- LEXX PE ratio analysis and historical PE chart
- LEXX PS ratio (Price-to-Sales) history and trend
- LEXX intrinsic value — DCF, Graham Number, EPV models
- LEXX stock price prediction 2025 2026 2027 2028 2029 2030
- LEXX fair value vs current price
- LEXX insider transactions and insider buying
- Is LEXX undervalued or overvalued?
- Lexaria Bioscience Corp financial analysis — revenue, earnings, cash flow
- LEXX Piotroski F-Score and Altman Z-Score
- LEXX analyst price target and Smart Rating
Lexaria Bioscience Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Lexaria Bioscience Corp (LEXX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Lexaria Bioscience Corp (LEXX) Key Strengths (1)
Revenue surging 107.10% year-over-year
Supporting Valuation Data
Lexaria Bioscience Corp (LEXX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 34.8x annual revenue
Very low institutional interest at 6.84%
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.6x book value
Supporting Valuation Data
Lexaria Bioscience Corp (LEXX) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 107.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (34.80), Price/Book (3.58) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -155.20%, Operating Margin at -2015.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -155.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 107.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LEXX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LEXX's Price-to-Sales ratio of 34.80x sits near its historical average of 34.53x (71th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 12% below its historical high of 39.51x set in Mar 2026, and 8% above its historical low of 32.18x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Lexaria Bioscience Corp (LEXX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Lexaria Bioscience Corp is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 522,000 with 107% growth year-over-year.
Key Findings
Revenue growing at 107% YoY, reaching 522,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 129% of revenue (671,340) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -989,197, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Lexaria Bioscience Corp maintain 107%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Lexaria Bioscience Corp.
Bottom Line
Lexaria Bioscience Corp is a high-conviction growth story with revenue accelerating at 107% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(1 last 3 months)
| Insider | Type | Shares |
|---|---|---|
BUNKA, CHRISTOPHER Director | Sell | -100,000 |
Data sourced from SEC Form 4 filings
Last updated: 12:57:03 PM
About Lexaria Bioscience Corp(LEXX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Lexaria Bioscience Corp. The company is headquartered in Kelowna, Canada.